Global Leading Market Research Publisher QYResearch announces the release of its latest report “Molecular Diagnostics Infectious Disease Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Molecular Diagnostics Infectious Disease Testing market, including market size, share, demand, industry development status, and forecasts for the next few years.
Why are clinical laboratories, hospitals, and public health agencies adopting molecular diagnostics for infectious disease testing over traditional methods? Traditional infectious disease detection methods (culture, serology, microscopy) face three critical limitations: slow turnaround time (bacterial culture requires 24–72 hours, viral culture 3–14 days), lower sensitivity (miss low-level infections, particularly in early stages), and inability to detect multiple pathogens simultaneously (each test targets one organism). Molecular diagnostics is a technique used to detect the presence of and identify genetic materials and proteins associated with specific health conditions, diseases, and infectious agents in body fluids such as blood, urine, or sputum. Molecular diagnostics for infectious disease testing is used by hospitals, academic institutions, laboratories, and public health agencies. Molecular diagnostics diagnoses diseases by detecting and analyzing biomarkers (DNA, RNA, proteins). In infectious disease testing, molecular diagnostics detects nucleic acid sequences of pathogens to determine whether infection is viral or bacterial. Unlike traditional methods requiring tedious culture steps, molecular diagnostics extracts nucleic acids directly from samples and performs rapid, accurate detection. This method offers high sensitivity, high specificity, and rapid response – enabling early disease detection, preventing disease spread, and controlling infectious disease outbreaks.
The global market for Molecular Diagnostics Infectious Disease Testing was estimated to be worth US$ 5,855 million in 2024 and is forecast to reach a readjusted size of US$ 9,400 million by 2031, growing at a CAGR of 7.1% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/3670518/molecular-diagnostics-infectious-disease-testing
Product Definition: What Is Molecular Diagnostics for Infectious Disease Testing?
Molecular diagnostics for infectious disease testing comprises techniques that detect pathogen-specific nucleic acids (DNA or RNA) in clinical specimens. Core technologies include: (a) Polymerase Chain Reaction (PCR) – amplifies target DNA sequences; real-time PCR (qPCR) quantifies pathogen load. Most common method (60–70% of molecular testing). (b) Nucleic Acid Amplification Testing (NAAT) – includes transcription-mediated amplification (TMA) and loop-mediated isothermal amplification (LAMP); faster than PCR, less thermal cycling equipment. (c) Next-Generation Sequencing (NGS) – identifies all pathogens in a sample (metagenomics), detects novel or unexpected pathogens, and provides antimicrobial resistance genotyping. (d) Multiplex Molecular Panels – detect 10–50 pathogens simultaneously from a single sample (e.g., respiratory panel: influenza A/B, RSV, COVID-19, rhinovirus, adenovirus, etc.; gastrointestinal panel: Salmonella, Shigella, Campylobacter, norovirus, etc.). (e) Point-of-Care (POC) Molecular Tests – compact, rapid (15–30 minutes), CLIA-waived devices for near-patient testing (e.g., Cepheid GeneXpert, Abbott ID NOW). Molecular diagnostics is widely used for: HIV (viral load monitoring, early infant diagnosis), hepatitis B and C (viral load, genotyping), tuberculosis (TB) – rapid molecular tests (GeneXpert MTB/RIF) detect TB and rifampicin resistance in 90 minutes vs. 4–6 weeks for culture, influenza and respiratory viruses (multiplex panels), COVID-19 (RT-PCR), sexually transmitted infections (chlamydia, gonorrhea, trichomoniasis), and emerging infectious diseases (Ebola, Zika, Mpox).
Market Segmentation: Pathogen Type and End-User
By Pathogen Type (Disease Category):
- Viral Infectious Disease Testing – Largest segment (45–50% of market value). HIV, hepatitis (B, C), COVID-19, influenza, RSV, CMV, EBV, Zika, dengue, Mpox.
- Bacterial Infectious Disease Testing – 35–40% of market value. Tuberculosis, chlamydia, gonorrhea, C. difficile, MRSA, Group B streptococcus, Lyme disease, H. pylori.
- Parasitic Infectious Disease Testing – 10–15% of market value. Malaria, toxoplasmosis, leishmaniasis, trypanosomiasis.
By End-User (Facility Type):
- Hospital – Largest segment (55–60% of market value). Central laboratories, emergency departments (rapid POC testing), infection control.
- Laboratory Research – 35–40% of market value. Reference laboratories (Quest, LabCorp), public health laboratories (CDC, WHO collaborating centers), academic research labs.
Key Industry Characteristics Driving Strategic Decisions (2025–2031)
1. The COVID-19 Legacy: Accelerated Adoption and Infrastructure Expansion
The COVID-19 pandemic (2020–2023) fundamentally transformed the molecular diagnostics landscape. Key changes: (a) massive installed base – RT-PCR instruments (e.g., Roche LightCycler, Thermo Fisher QuantStudio, Cepheid GeneXpert) deployed globally (100,000+ instruments); (b) trained workforce – thousands of laboratory technologists trained in molecular techniques; (c) regulatory flexibility – FDA Emergency Use Authorizations (EUAs) streamlined approval pathways; (d) reimbursement expansion – Medicare, Medicaid, and private insurers cover molecular testing for infectious diseases. Post-pandemic, this infrastructure is being repurposed for other infectious diseases (respiratory panels, STI testing, TB, hepatitis). The installed base ensures continued market growth even as COVID-19 testing declines.
2. Technical Challenge: Multiplexing Capacity and Cost
The primary technical challenge for molecular diagnostics is balancing multiplexing capacity (detecting many pathogens in one test) with cost per test. High-plex panels (20–50 targets) require complex assay design, expensive reagents, and sophisticated analysis software. For example, a respiratory panel that detects 20 viruses and bacteria costs US$50–150 per test – acceptable for hospitalized patients but too expensive for outpatient screening. Lower-plex panels (2–5 targets) cost US$20–40 per test. Manufacturers are developing: (a) syndromic panels – targeted at specific clinical presentations (respiratory, gastrointestinal, meningitis/encephalitis, bloodstream infections); (b) tiered testing – rapid low-plex POC test first (US$10–20), followed by high-plex confirmatory if negative; (c) open-architecture platforms – labs can design custom panels (e.g., Luminex xMAP, Qiagen QIAstat-Dx). The optimal multiplexing level depends on clinical setting (ED: rapid low-plex; hospitalized: high-plex for definitive diagnosis).
3. Industry Segmentation: Centralized Lab vs. Point-of-Care vs. At-Home
The molecular diagnostics infectious disease testing market segments by testing location.
Centralized laboratory testing (high-volume reference labs, hospital central labs) – 60–65% of market value, 6–7% CAGR. High throughput (100–1,000+ tests/day), high-plex panels, batch processing, lower cost per test (US$10–50). Dominant for HIV viral load, hepatitis, TB, and reference testing.
Point-of-Care (POC) molecular testing (ED, urgent care, physician offices, pharmacy clinics) – 25–30% of market value, 8–10% CAGR – fastest-growing. Rapid results (15–60 minutes), CLIA-waived devices, near-patient testing. Used for flu/RSV/COVID-19, Strep A, STIs, TB (GeneXpert). Cost per test: US$20–60.
At-home molecular testing (direct-to-consumer, telehealth-enabled) – 5–10% of market value, 12–15% CAGR – emerging. Self-collected samples (nasal swab, saliva, urine), mailed to lab or processed on home device (e.g., Cue Health, Lucira). COVID-19 at-home molecular tests paved the way; STI and respiratory panels are emerging.
4. Recent Market Developments (2025–2026)
- F. Hoffmann-La Roche (October 2025) launched a high-throughput molecular diagnostics platform (cobas 9800) with 1,000 tests per hour capacity, integrating PCR, NGS, and multiplex capabilities for respiratory, bloodborne, and STI testing.
- bioMérieux (November 2025) received FDA 510(k) clearance for a bloodstream infection (sepsis) multiplex panel (BioFire BCID2) detecting 40 pathogens and 8 resistance genes in 60 minutes, reducing time to appropriate antibiotics (from 24–48 hours to 1 hour).
- Cepheid (Danaher) (December 2025) launched a 4-in-1 respiratory POC test (COVID-19, Flu A, Flu B, RSV) with 25-minute turnaround, CLIA-waived, for physician offices and urgent care centers.
- FDA (January 2026) published final guidance on “Multiplex Molecular Panels for Respiratory Infections,” providing clear regulatory pathway for 20+ target panels, reducing approval time from 12–18 months to 6–9 months.
- CDC (February 2026) announced a US$500 million Molecular Diagnostics Expansion Program, funding molecular testing capacity (instruments, training, reagents) for 200 public health laboratories and 1,000 hospital labs for emerging infectious disease preparedness.
5. Exclusive Observation: The Convergence of Molecular Diagnostics and Antimicrobial Stewardship
Molecular diagnostics is becoming integral to antimicrobial stewardship programs (ASP). Rapid molecular tests that identify pathogens and resistance genes enable: (a) targeted therapy – de-escalation from broad-spectrum to narrow-spectrum antibiotics (e.g., MRSA PCR negative allows discontinuation of vancomycin, reducing nephrotoxicity); (b) resistance detection – early identification of carbapenem-resistant Enterobacteriaceae (CRE) or methicillin-resistant S. aureus (MRSA), triggering infection control measures; (c) antibiotic de-escalation – negative viral panel avoids unnecessary antibiotics for viral respiratory infections. A 2025 study of 10 hospitals implementing rapid molecular testing for bloodstream infections found: (a) time to effective antibiotic therapy reduced from 30 hours to 6 hours; (b) hospital length of stay reduced by 2.5 days; (c) antibiotic costs reduced by US$500–1,000 per patient; (d) 30-day mortality reduced by 15–20%. For hospitals, the ROI of molecular diagnostics extends beyond test reimbursement to improved patient outcomes and reduced antibiotic resistance.
Key Players
Abbott Laboratories, BD, bioMérieux, Thermo Fisher Scientific, F. Hoffmann-La Roche, Siemens AG, Veridex, Luminex, GenMark Diagnostics, Qiagen NV, Genomix Biotech, BioTheranostics, GenMark Diagnostics.
Strategic Takeaways for Clinical Lab Directors, Hospital Administrators, and Investors
- For clinical laboratory directors: Implement multiplex molecular panels for respiratory, gastrointestinal, and bloodstream infections. The cost per test (US$50–150) is offset by reduced length of stay (2–3 days, US$2,000–6,000 savings per patient) and targeted antibiotic therapy (US$500–1,000 savings per patient). POC molecular testing (GeneXpert, BioFire) in EDs reduces admission rates for viral illnesses.
- For hospital administrators and infection control: Molecular diagnostics for antimicrobial stewardship reduces antibiotic resistance rates and C. difficile infections. Rapid viral testing (flu, RSV, COVID-19) enables cohorting (reducing nosocomial transmission).
- For investors: The 7.1% CAGR for the overall market understates growth in the POC molecular subsegment (8–10% CAGR), the at-home testing subsegment (12–15% CAGR), and the multiplex panel subsegment (9–11% CAGR). Target companies with (a) high-plex syndromic panels (20+ targets), (b) POC/CLIA-waived molecular devices, (c) antimicrobial resistance genotyping capabilities, and (d) emerging infectious disease preparedness (platform flexibility). Molecular diagnostics has been widely used in the detection of various infectious diseases – AIDS, hepatitis, tuberculosis, influenza, COVID-19 – providing important support for infectious disease prevention and control.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
